In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Linda K Rushworth; Victoria Harle; Peter Repiscak; William Clark; Robin Shaw; Holly Hall; Martin Bushell; Hing Y Leung; Rachana Patel

doi:10.26508/lsa.202000770

Research Article

Open Access

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, View ORCID ProfileHolly Hall, Martin Bushell, View ORCID ProfileHing Y Leung Correspondence email, Rachana Patel

Linda K Rushworth

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Victoria Harle

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter Repiscak

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William Clark

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robin Shaw

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Holly Hall

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Holly Hall

Martin Bushell

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hing Y Leung

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Hing Y Leung
For correspondence: h.leung@beatson.gla.ac.uk

Rachana Patel

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Published 8 October 2020. DOI: 10.26508/lsa.202000770

Article
Figures & Data
Info
Metrics
Reviewer Comments
PDF

Statistics from Altmetric.com

Article usage

Article usage: October 2020 to January 2021

	Abstract	Full	Pdf
Oct 2020	36	278	142
Nov 2020	9	209	103
Dec 2020	29	181	90
Jan 2021	7	84	40

PreviousNext

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Message Subject (Your Name) has sent you a message from Life Science Alliance

Message Body (Your Name) thought you would like to see the Life Science Alliance web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

In vivo CRISPR screen identifies TCEAL1 to enhance docetaxel